Chance of hepatocellular carcinoma halved in hep C patients on antivirals

Danish reviewers analysed data from eight comparative treatment trials involving 3200 patients whose hepatitis C infection resulted in chronic inflammation and fibrosis or cirrhosis.

Most of the patients studied were on interferon monotherapy
with only two trials using pegylated interferon and one using interferon
plus ribavirin.

Patients whose treatment cleared the virus long term were much less likely to develop liver cancer than non-responders although the latter still showed a benefit from the drugs .

The study suggested patients receiving the current standard